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Abstract
Background: Primary hyperoxaluria type I (PH1) is a rare genetic disorder characterized by allelic and clinical
heterogeneity. Four mutations (G170R, 33_34insC, I244T and F152I) account for more than 50% of PH1 alleles and
form the basis for diagnostic genetic screening for PH1. We aimed to analyze the prevalence of these specific
mutations causing PH1, and to provide an accurate tool for diagnosis of presymptomatic patients as well as for
prenatal diagnosis in the affected families.
Methods: Polymerase chain reaction/Restriction Fragment Length Polymorphism, were used to detect the four
mutations in the AGXT gene in DNA samples from 57 patients belonging to 40 families.
Results: Two mutations causing PH1 were detected in 24 patients (42.1%), with a predominance of the I244T
mutation (68% of patients) and 33_34insC (in the remaining 32%). In 92% of cases, mutated alleles were in
homozygous state.
The presented clinical features were similar for the two mutations. The age of onset was heterogeneous with a
higher frequency of the pediatric age. In 58.3% of cases, the presentation corresponded to advanced renal disease
which occurred early (< 5 years) in the two mutations. In adolescents, only the I244T mutation was detected
(41.1%). I244T and 33_34insC mutations were observed in adult patients, with 17.6% and 12.5% respectively.
Conclusion: Limited mutation analysis can provide a useful first line investigation for PH1. I244T and 33_34insC
presented 28.2% of identified mutations causing disease in our cohort. This identification could provide an accurate
tool for prenatal diagnosis in the affected families, for genetic counselling and for detection of presymptomatic
individuals.
Background
Primary hyperoxaluria (PH) is a rare autosomal-recessive
disorder of endogenous oxalate synthesis. Deficiencies of
alanine-glyoxylate aminotransferase (AGT) [1] or glyox-
ylate reductase (GRHPR) [2] are the known causes of
the two first types of the disease (PH I and II, respec-
tively). Recently, mutations in DHDPSL gene, encoding
4-hydroxy-2-oxoglutarate aldolase, catalyzing the final
step in the metabolic pathway of hydroxyproline, has
been described as the principal cause of the third type
of PH (PH III) [3].
Type I PH is still the most frequent described form of
the disease caused by the absence, the deficiency, or the
mistargeted activity of the AGT, a liver-specific peroxiso-
mal enzyme (EC 2.6.1.44). The AGT catalyses the transa-
mination of the glyoxylate to glycine. The AGT deficiency
induces the conversion of glyoxylate to oxalate which is
excreted at high levels by the kidney [1]. The elevated
urinary oxalate concentration leads to the formation of
insoluble calcium oxalate (CaOx) crystals and subse-
quently, to urolithiasis, nephrocalcinosis followed by pro-
gressive renal damage, renal failure, and reduced life
expectancy. The oxalates are then progressively deposited
in many other tissues, leading to systemic oxalosis [4].
* Correspondence: asmaomezzine@yahoo.fr
1Biochemistry Department, Sahloul University Hospital, Sousse, Tunisia
Full list of author information is available at the end of the article
Mbarek et al. BMC Nephrology 2011, 12:25
http://www.biomedcentral.com/1471-2369/12/25
© 2011 Mbarek et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.The clinical presentation of the disease is highly het-
erogeneous with respect to residual enzymatic activity,
age at onset, type of presentation, severity of hyperoxa-
luria, and progression to renal failure. Most patients suf-
fer from recurrent episodes of nephrolithiasis in
childhood or adolescence. The infantile form of oxalosis
is diagnosed only in few cases, a factor that often leads
to death from renal failure during the first months of
life. An increasing number of patients are diagnosed
only in adulthood, usually after a long-standing history
of recurrent nephrolithiasis and sometimes after starting
dialysis treatment or after kidney transplantation [5].
The incidence and severity of PH1 vary in different
geographic regions. It is much more prevalent in Medi-
terranean countries [6,7]. In Tunisia, for example, it
accounts for 13.5% of cases of ESRD in children com-
pared with only 0.7% in North America [8].
The AGT enzyme is encoded by the single copy gene
(AGXT), consisting of 11 exons spanning over 10 kb
DNA that maps to chromosome 2q37.3 [9] and encodes
a 392-residue polypeptide with molecular weight of 43
kDa [10]. The two most common intragenic haplotypes
for the normal AGXT gene are referred to as the major
(Ma) and minor (Mi).
145 causing disease mutations were described in PH1
[11], which four (c.508G > A (p.G170R), c.33_34insC
(p.K12QfsX156), c.731T > C (p.I244T) and c.454T > A
(p.F152I)) account for more than 50% of PH1 alleles
and form the basis for diagnostic genetic screening for
PH1 [12].
The aim of our study is to analyze the prevalence of
these specific mutations causing PH1, and to provide an
accurate tool for diagnosis of presymptomatic patients
as well as for prenatal diagnosis in the affected families.
Methods
Subjects
Between 2002 and 2010, one hundred-five subjects from
40 families were enrolled in this study. 46 were consid-
ered as reported cases, 24 male and 22 female, admitted
by paediatric and adult nephrologists from different spe-
cialized centres in Tunisia for suspected PH1. Ages at
presentation ranged from 3 months to 61 years (mean
16 ± 14.4 yr). Fifty-nine relatives of 22 patients have
been diagnosed by family screening. Eleven additional
patients have been diagnosed by families’ screening of
which 5 were in presymptomatic state and maintained
normal renal function.
We consider in our study a highly selected cohort of
patients and not a population-based sample. Clinical
details of patients were described in Additional file 1,
T a b l eS 1 .B a s e do nt h er a p i de v o l u t i o no fE S R D ,c l i n i c a l
and biochemical findings, and systemic oxalosis, PH1 is
the most suspected diagnosis among our patients. In fact,
all index cases were already with chronic renal failure
(CRF) when diagnosed and required renal replacement
therapy. Urolithiasis and/or nephrocalcinosis were present
in all cases. Elevated urinary oxalate or oxalate/creatinine
ratio was noted in most of cases. Diagnosis was supported
in some cases by renal biopsy and stone analysis.
Molecular approach
After obtaining parental or patients’ consent, genomic
DNA was isolated from peripheral blood leucocytes, as
described previously [13]. The c.33_34insC (p.
Lys12GlnfsX156), c.508G > A (p.G170R), c.731T > C (p.
I244T) and c.454T > A (p.F152I) mutations in AGXT
were analysed by amplification of genomic DNA and
restriction enzyme digestion using primers and condi-
tions previously documented [14-16]. The PCR/restric-
tion enzyme test designed to detect c.33_34insC, was
used simultaneously to detect the mutation and to dis-
tinguish the Ma and Mi alleles [14].
Because of the lack of specialized labs to measure the
AGT activity in Tunisia, and due to the difficulties of the
transfer of samples abroad, no liver biopsy was carried
out on our patients. In order to decrease supersaturation
with oxalate, most cases undertake hyperhydration and
pyridoxine (vitamin B6) supplementation.
Ethical approval
The parents of the children and adult patients, provided
informed consent to the diagnostic and therapeutic proce-
dures involved, in agreement with the guidelines approved
by our institutional clinical research ethics committee.
Results
Clinical aspect of patients
Based on the age at onset (Table 1), 52.1% of index
cases patients (24/46) had a childhood oxalosis, in
which 17.4% (8/46) had infantile oxalosis (age < 1 yr).
The disease was diagnosed during adolescence in 17.4%
(8/46) patients and 30.4% (14/46) had an adult form.
Clinically, PH1 was highly heterogeneous and patients
presented several symptoms at the time of diagnosis
(Table 1). The circumstances of PH1 discovery corre-
sponded mainly to manifestations of ESRF. In eight
cases, the manifestations were non specific such as ane-
mia, diarrhea, vomiting and convulsions.
Twenty-two of 46 patients (47.8%) had a positive
family history for recurrent urolithiasis. 17.4% of
patients had renal failure associated to nephrocalcinosis,
45.6% had recurrent nephrolithiasis, whereas 37% pre-
sented a combined form of urolithiasis and nephrocalci-
nosis. Systemic features of oxalosis, included ocular,
hepatic, cardiac and bone damaging, which occurred in
39% of patients. We reported a high consanguinity
levels, noted in 30/40 families (75%).
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c.508G > A, c.731T > C and 454T > A mutations.
Family studies were carried out to test the other sib-
lings, if they existed, and to confirm that the parents
were heterozygous for the mutations present in their
offspring. Mutations causing disease were characterised
in 24 patients belonging to 13 of the 40 families (32.5%)
(Table 2 and Additional file 2, Table S2). Nine of the 13
families carried I244T mutations, while 4 families car-
ried c.33_34insC mutation. Neither G170R nor F152I
mutations were detected in our cohort of patients.
The I244T mutation
I244T mutation was identified in 17 patients of whom 9
were index cases. The additional 8 patients were identi-
fied by family screening. They originated from central
and south Tunisia with 41.1% in each. All patients had
renal symptoms at the time of diagnosis, except 4 (2
children and 2 adults) of the 8 patients founded by
family screening, who were presymptomatic at the time
of diagnosis.
I244T was detected in 16 cases in homozygous state
and one case in heterozygous state. Consanguinity was
reported in 7/9 families (77.7%). The median age of dis-
ease detection was 13 yr (range 3 month-38 years), with
variable age of onset (Table 2).
Infantile and early childhood PH1
Seven patients (41.1%) were symptomatic during infancy
and early childhood; five of them reached ESRD while
two had a reduced renal function. Urolithiasis was
observed in one patient, three had nephrocalcinosis and
one had both of urolithiasis and nephrocalcinosis.
Adolescent PH1
PH1 was diagnosed at the time of ESRD in 7 patients
(41.1%) with adolescent form. Three out of these pre-
sented without evident nephrocalcinosis or urolithiasis.
Adult PH1
Two of the three adult patients with I244T mutation
were found by family screening and conserved a normal
renal function despite of their two children were in
ESRD, at 4 years and 8 months. Oxaluria of the two
Table 1 Characteristics of index cases and families with
suspected PH1
Characteristics of index cases (n = 46)
Median and [range]of age( years) 13 [range 0.25 - 61]
Sex-ratio (male/female) 1.09 (24/22)
Oxalate/creatinine (mmol/mmol) 0.37 ± 0.71
Mortality (6)
Systemic symptoms (18)
Age of patients at presentation (n = 46) %
< 1 yr (8) 17.4
1-10 yr (16) 34.7
11-20 yr (8) 17.4
> 20 yr (14) 30.4
Renal insufficiency
with nephrocalcinosis only (8) 17.4
with urolithiasis (21) 45.6
With both nephrocalcinosis and urolithiasis (17) 37
CRF (13) 28.2
ESRD
Hemodialysis (26) 56.5
Peritoneal Dialysis (7) 15.2
Characteristics of families (n = 40) %
Geographic origin of families
North (2) 5
Centre (8) 20
Sahel (11) 27.5
South (19) 47.5
Consanguinity in families
Present (30) 75
Absent (10) 25
Oxalate/creatinine (mmol/mmol) ratio with relevant reference for age as
reported by Belhaj et al 2009 (22): 0-6 months: 0.36; 7-24 months: 0.17;
2-5 years: 0.10; > 5 years: 0.081.
Table 2 Characteristics of patients with detected
mutations
Characteristics of patients I244T
mutation*
N=1 7
33_34insC
mutation*
n=8
Median and [range ] of ages of onset
(years)
12 [0.25 -
38]
3[0.33 - 61]
Oxalate/creat (mmol/mmol) 0.6 ± 0.95 0.17 ± 0.15
Different ages of onset (number of
patients)
%
< 1 yr (2) 11.7 (1) 12.5
2-5 yr (5) 29.4 (6) 75
10-20 yr (7) 41.1 -
> 20 yr (3) 17.6 (1) 12.5
Consanguinity (12) 70.5 (8) 100
Renal insufficiency (13) 76.4 (7) 87.5
with nephrocalcinosis only (3) 17.6 (0) 0
with urolithiasis (3) 17.6 (6) 75
with both nephrocalcinosis and
urolithiasis
(4) 23.5 (1) 12.5
Data not done (3) 17.6 - -
ESRD (13) 76.4 (7) 87.5
Hemodialysis (11) 64.7 (7) 87.5
Peritoneal Dialysis (2) 11.7 (0) 0
Preserved renal function (4) 23.5 (1) 12.5
Systemic symptoms (4) 23.5 (2) 25
Mortality (5) 29.5 (5) 62.5
* All patients with homozygote and heterozygote mutations were considered;
The patient carrying compound heterozygote mutations (I244T and 33_34ins)
was considered in the two columns.
**Characteristic of patients with homozygote mutations are described in
Additional file 2, Table S2.
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urolithiasis. The third adult patient was diagnosed at
ESRD with nephrocalcinosis and urolithiasis.
Outcome
Of the 13 patient with acute renal failure at presenta-
tion, five eventually developed ESRD and had dialysis
replacement therapy. Five died of PH1 at a median age
of 16 years old (range 3-18 years).
The 33_34insC mutation
Seven of the eight patients carrying 33_34insC mutation
were female (sex-ratio = 0.1). They originated from cen-
tral and south Tunisia with 50% in each. The median
age of patients at presentation was 3 years (range 5
months - 61 years). Seven patients were identified before
the age of 6 year; five of them were already in ESRF at
presentation. Only one adult patient, 61 years old, was
identified suffering ESRD with urolithiasis and hyperure-
ceamia. nephrocalcinosis and urolithiasis were detected
only in one patient, while 62.5% of patients were pre-
sented with urolithiasis. Five of the eight patients
(62.5%) died of their disease within the age of 5 years.
Six of the eight patients had Ma/Ma alleles and car-
ried 33_34insC in homozygote state and had ESRD. The
two other patients belong to family F1. The patient F1-1
of a five month old month has a Ma/Mi allele and car-
ried compound heterozygous mutations, in which
33_34insC is noted. Family screening detected his 6
year-old sister with Ma/Ma alleles and compound het-
erozygous mutations, 33_34insC and I244T. Interest-
ingly, her renal function was preserved until her last
follow up at 10 years-old. However, the patient F1-1
died of his disease at the age of 6 months.
Discussion
PH1 is considered as a rare genetic disorder charac-
terised by allelic and clinical heterogeneity. We reported
57 patients belonging to 40 families, with one or more
affected members (Additional file 3, Figure S1). It was
reported that PH1 is particularly frequent in Tunisia [8].
The prevalence of PH1 was estimated by Chemli et al.
to be 5.5/10
6 population [17]. It remains underreported
with an estimated prevalence ranging from 1 to 3/10
6
population in Europe and North America, respectively
[18]. An increased frequency of PH1 has been also
reported in Middle East countries [19-21] as a result of
the high rate of consanguinity in these populations. In
our cohort, consanguinity was reported in 75% of
families, mainly originated from the centres and the
south of the country (Table 1), where the consangui-
neous marriage is still a frequent custom.
Similar to most Tunisian reports [8,17,22], we showed
a high frequency of PH1 among children referred to our
centre of Pediatric Nephrology, that recruits all cases
from central and southern regions of the country. How-
ever, we believe that the incidence of PH1 may be
higher in adults than we reported, because our results
represent adult cases referred only to the two centres of
adult nephrology in the region of Sahel. The adolescent
form of the disease was described in only 17.4% (8/46)
of patients. By comparison, European studies reported
approximately 10% of affected individuals presented
with severe disease before the age of six months and
80%-90% of affected individuals present in late child-
hood or early adolescence [23].
We noted that all the index cases were in CRF and
ESRD at diagnosis with a wide variability in clinical pre-
sentation. The most severe form of the disease was
observed in patients before the age of eight months
(17.4% (8/46)). In this group, symptoms of PH1 included
nephrocalcinosis (17.4% (8/46)) with or without nephro-
lithiasis (37% (17/46) and 45.6% (21/46) respectively),
failure to thrive (37%), and urinary tract infection (50%).
Early death was common 6/46 (13%). The youngest
infantile patients were presented with non specific
symptoms such as failure to thrive. Older patients had
symptoms that are often related to the urinary tract and
systemic oxalosis in 39%.
In the absence of the liver biopsy, that provides a defi-
nitive diagnosis of hyperoxaluria [12], molecular genetics
has the potential to offer a rapid and non invasive
method to establish the diagnosis of PH1. There are
now more than 145 polymorphisms and mutations iden-
tified in the AGXT gene [11]. Whole gene sequence ana-
lysis is feasible, but the cost is not insignificant in our
country. For this reason, and as first line test, we
decided to search I244T, (known to be frequent in
Tunisia) and G170R, F152I and 33_34insC mutations
that recur frequently and form the basis of DNA screen-
ing panels in European countries [12]. We decide to
start by studying those mutations because there is not
available information about the others mutations fre-
quent in Tunisia.
We have detected two mutations causing disease,
I244T and 33_34insC, in 13 of the 46 index cases
(28.2%). After families investigations the number of
affected patients increased to 24 patients (42% (24/57)),
belong to 13 of the 40 families (32.5%). I244T and
33_34insC mutations have alleles frequencies of 68%
and 32% respectively, in patients with detected muta-
tions. These frequencies were more elevated than those
reported by Rumsby et al, in the mutational screening
of the three common mutations (33_34insC, G170R and
I244T) which avoid liver biopsy in 34.5% of patients
[12].
Homozygous I244T and 33_34insC mutations were
the most frequent among identified mutations in our
patients. This phenomenon could be explained by the
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families belong. Actually, consanguinity can play an
important role in the inheritance of the disease and can
deepen the molecular diversity and the heterogeneity of
PH. But taking into account the consanguinity, we
should expected much more patients carrying these
mutations alones or in compound heterozygotes for
both. This may be explained by the possibility of exist-
ing of other frequent mutations (not identified) in our
study.
I244T, also called ‘mutation Maghrebin’ [22], occurs
on the minor allele of AGXT [12]. It leads to AGT mis-
folding, which produces functionally inactive aggregates.
This mutation seems to be the most detected in our
population. Its frequency was considerably higher than
frequencies reported in previous studies among Tuni-
sians and other populations such as Spanish and North
African background [12,17,22,24-26].
I244T appears to constitute the only PH1 mutation
associated with a founder effect. A North African origin
could be speculated, various patients, natives of the
Canary Islands where I224T mutation was frequent
(92%), are thought to be originated from Northwest
Africa[27].
In addition, we detected a main incidence 41.1%,
among childhood and adolescent patients, and only
17.6% were presented in adulthood. However, in Canary
Island, all carriers of I244T mutation were diagnosed in
adulthood, with severe renal stone disease and ESRF [26].
The age of onset and the symptoms of the disease
seem to be variable and can be influenced by other fac-
tors. We have detected two uncommon cases with
pseudo-dominant inheritance in two consanguineous
families F17 and F40. Withi nt h es a m em u t a t i o n ,t h e
clinical progression was quite different between patients
and their fathers, although they have the same genotype
(I244T/I244T). In fact, at presentation, the two children
were in ESRD, at 4 years and 8 months respectively. But
their fathers maintained normal renal function at the
age of 40 till 36. Clinical analysis detected urolithiasis in
the father of F17. This great molecular heterogeneity of
PH1 can be explained by differences in activity level of
other enzymes important in oxalate synthesis, modifier
genes, the quantity of oxalate precursors in the diet,
renal oxalate handling, absorption of dietary oxalate,
hydration status, infections, and urinary crystallization
factors [28].
The 33_34insC mutation, was the second mutation
detected in our patients with alleles frequency of 32%,
more elevated than other reports (12 to 13%) [12,14,29].
It was first described in Italian patients [29]. This micro-
insertion occurs on major or minor allele of AGXT and
it was considered as the most common PH1 mutation
on the major allele (31%) [14]. It has been reported that
homozygous, would be expected to have no immunor-
eactive protein and no catalytic activity [30]. In our
study, seven of the 8 detected patients were homozygous
for the mutation and associated with ESRD. 87.5% of
detected patients carrying 33_34insC mutation were
female, with a median age of 3 years, and only one case
in adulthood in the sixth decade of life. Clinically, chil-
dren carrying this mutation suffered a very severe form
of PH1, 62.5% (5/8) of them died of their disease.
Nevertheless a mild form of disease with B6 treatment
responsiveness was exceptionally observed in the adult-
hood [31]. Curiously, our adult patient preserved her
renal function until the age of 60 without B6 treatment.
She progressed rapidly to ESRF, because she was diag-
nosed late after the onset of renal insufficiency and had
no medical follow-up. This age and clinical variation
m a yb ee x p l a i n e db yi n t e r a c t i o n so f3 3 _ 3 4 i n s Cw i t h
other genes and/or environmental factors.
G170R, F152I were absent in our cohort, in spite of
their high frequencies in Caucasians populations, respec-
tively 40 and 7% of disease alleles [16,32,33].
In Summary, I244T and 33_34insC mutations were
associated with a molecular and phenotypic variation in
our cohort. They were identified in 42% of patients in
which 28.2% were index case and 11 patients were dis-
covered by family screening. Five of the 11 patients
were presymptomatic and prenatal diagnosis was per-
formed in two families. So a preliminary detection of
these limited mutations in the AGXT gene can serve as
useful tool in the families screening of patients with
demonstrated PH1. If a mutation is known, direct detec-
tion of the mutation can be used for diagnosis of pre-
symptomatic patients as well as for prenatal diagnosis
[30]. 71.7% (33/46) of our index case patients were
negative for the common tested mutations and in whom
a diagnosis of PH could not be excluded, other frequent
mutations screening followed by whole gene sequencing
will be done forthcoming for these patients if no known
frequent mutation is found.
Concerning treatment, our patients systematically
received vitamin B6, but analysis of pyridoxine respon-
siveness was not possible in patients with ESRF. It was
reported that in pyridoxine sensitive patients an
improvement in renal function and a decrease in plasma
and urine oxalate with high-dose vitamin B6 therapy
were noted [34]. Pyridoxine responsiveness seems to be
genotypes dependent. It has clearly been demonstrated
in the G170R mutation, and even been observed in a
patient with F152I and 33_34insC [35].
Early treatment of presymptomatic patients is possible,
and may prevent further loss of renal function. How-
ever, patients with early renal failure, classic conserva-
tive measures are often insufficient and patients require
renal replacement therapy.
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noted a high rate of mortality in our patients (41.6%),
66% of them were in childhood. This can be explained
by the absence of rapid kidney-liver transplantation,
which has excellent outcome according to European and
the US Registries [36,37]. In fact, it showed greater
graft-survival than in isolated kidney transplantation
[38].
The limitation of our study is the number of tested
mutations. We admit that our data can not exactly eval-
uate the PH mutations frequency in Tunisia, and the
existence of other frequent mutations is possible. But
with our limited means, we can not deny the usefulness
of mutation-based diagnosis testing that allowed us to
identify mutations in considered number of patients. In
addition we have identified presymptomatic analyzed
patients, thereby providing a targeted prenatal diagnosis.
For more general conclusions, our results need to
identify the PH mutations in the rest of analysed
patients.
Conclusion
Primary hyperoxaluria, is a rare metabolic disease that
seem to provide a high morbidity and severe infantile
PH1. I244T and 33_34insC presented 28.2% of identified
mutations causing disease in our cohort. The prelimin-
ary screen for limited mutations in the AGXT gene can
serve as a useful first line investigation for the diagnosis
of PH1, and provide a quicker diagnosis at lower cost
than whole-gene sequencing. Identification of a given
mutation could provide an accurate tool for prenatal
diagnosis in the affected families, allowing for genetic
counselling and for the detection of presymptomatic
individuals for timely medical management.
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